BlackRock’s Hepion Pharmaceuticals HEPA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-1,658
| Closed | -$713 | – | 5515 |
|
|
2025
Q1 | $713 | Sell |
1,658
-1
| -0.1% | -$10 | ﹤0.01% | 5341 |
|
|
2024
Q4 | $39K | Hold |
1,659
| – | – | ﹤0.01% | 4998 |
|
|
2024
Q3 | $55.6K | Hold |
1,659
| – | – | ﹤0.01% | 4790 |
|
|
2024
Q2 | $84.6K | Hold |
1,659
| – | – | ﹤0.01% | 4741 |
|
|
2024
Q1 | $207K | Hold |
1,659
| – | – | ﹤0.01% | 4569 |
|
|
2023
Q4 | $269K | Hold |
1,659
| – | – | ﹤0.01% | 4568 |
|
|
2023
Q3 | $414K | Sell |
1,659
-56
| -3% | -$20.9K | ﹤0.01% | 4479 |
|
|
2023
Q2 | $900K | Buy |
1,715
+112
| +7% | +$68.7K | ﹤0.01% | 4318 |
|
|
2023
Q1 | $1.24M | Buy |
1,603
+5
| +0.3% | +$3.69K | ﹤0.01% | 4256 |
|
|
2022
Q4 | $480K | Buy |
1,598
+5
| +0.3% | +$2.11K | ﹤0.01% | 4612 |
|
|
2022
Q3 | $805K | Sell |
1,593
-22
| -1% | -$13.4K | ﹤0.01% | 4561 |
|
|
2022
Q2 | $924K | Buy |
1,615
+2
| +0.1% | +$1.67K | ﹤0.01% | 4563 |
|
|
2022
Q1 | $2.08M | Sell |
1,613
-11
| -0.7% | -$12.2K | ﹤0.01% | 4375 |
|
|
2021
Q4 | $1.85M | Sell |
1,624
-10
| -0.6% | -$13.7K | ﹤0.01% | 4431 |
|
|
2021
Q3 | $2.5M | Sell |
1,634
-16
| -1% | -$25.6K | ﹤0.01% | 4232 |
|
|
2021
Q2 | $3.27M | Sell |
1,650
-66
| -4% | -$121K | ﹤0.01% | 4062 |
|
|
2021
Q1 | $3.16M | Buy |
1,716
+522
| +44% | +$1.14M | ﹤0.01% | 4144 |
|
|
2020
Q4 | $2.62M | Buy |
1,194
+1,133
| +1,857% | +$2.94M | ﹤0.01% | 3956 |
|
|
2020
Q3 | $189K | Hold |
61
| – | – | ﹤0.01% | 4420 |
|
|
2020
Q2 | $173K | Hold |
61
| – | – | ﹤0.01% | 4393 |
|
|
2020
Q1 | $107K | Hold |
61
| – | – | ﹤0.01% | 4340 |
|
|
2019
Q4 | $325K | Buy |
+61
| New | +$236K | ﹤0.01% | 4237 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 5012 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 5038 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 4867 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 4877 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 4824 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 4771 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 4640 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 4555 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 4529 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 4586 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 4342 |
|
Other funds holding HEPA
BlackRock's HEPA Position: Q2 2025 in Review
BlackRock sold out of Hepion Pharmaceuticals (HEPA) in Q2 2025, closing a stake of 1,658 shares — an estimated $713 sold.
BlackRock first reported a position in HEPA in Q4 2019 and held it in 22 quarters. The position peaked at $3.27M in Q2 2021. 4 funds tracked by Wall St. Rank hold HEPA as of Q2 2025.
- BlackRock reported no remaining Hepion Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
- BlackRock sold 1,658 Hepion Pharmaceuticals shares in Q2 2025, an estimated $713.
- BlackRock first reported a position in Hepion Pharmaceuticals in Q4 2019 and held it in 22 quarters.
- BlackRock's Hepion Pharmaceuticals position peaked at $3.27M in Q2 2021.
- 4 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q2 2025.
Based on BlackRock's 13F filing for Q2 2025, filed 12 Aug 2025.